Ligand Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 4 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 244.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Ligand Pharmaceuticals Inc is 8.73, ranking 24 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 59.67M, representing a year-over-year increase of 39.37%, while its net profit experienced a year-over-year increase of 244.06%.
Key Metrics
The current valuation score of Ligand Pharmaceuticals Inc is 7.25, ranking 84 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 32.88, which is 165.72% below the recent high of 87.38 and 1786.11% above the recent low of -554.46.
The current earnings forecast score of Ligand Pharmaceuticals Inc is 8.89, ranking 7 out of 157 in the Pharmaceuticals industry. The average price target is 232.50, with a high of 275.00 and a low of 220.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Ligand Pharmaceuticals Inc is 7.53, ranking 12 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 226.81 and the support level at 177.61, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Ligand Pharmaceuticals Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 104.07%, representing a quarter-over-quarter increase of 1.63%. The largest institutional shareholder is The Vanguard, holding a total of 2.07M shares, representing 10.38% of shares outstanding, with 2.41% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ligand Pharmaceuticals Inc is 7.80, ranking 34 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Ligand Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
